TradesZ
Top 10 stocks to add now
← All stocks
AKBA

AKBA — AKEBIA THERAPEUTICS, INC.

CIK 1517022 · SEC EDGAR fundamentals

Latest 10-K filed February 26, 2026 · period ending December 31, 2023

Headline figures

Revenue
$0

Top-line sales for the most-recent fiscal year

FY2015 · 10-K

Net income
-$51.9M

Profit after all expenses, taxes, interest

FY2025 · 10-K

EPS (diluted)
-$0.28

Net income per diluted share outstanding

FY2025 · 10-K

Op. cashflow
-$23.4M

Cash actually generated by the business

FY2025 · 10-K

Balance sheet

Total assets
$220.7M

Everything the company owns

FY2025 · 10-K

Total liabilities
$269.9M

Everything the company owes

FY2025 · 10-K

Stockholders equity
$5.2M

Assets minus liabilities (book value)

FY2025 · 10-K

Long-term debt
$38.7M

Debt due more than 12 months out

FY2025 · 10-K

Revenue history

Revenues · FY values from Revenues

Fiscal year Revenue vs prior Source
FY2015 $0 10-K
FY2014 $0 10-K

Read the source

All figures on this page were filed by AKEBIA THERAPEUTICS, INC. with the SEC and pulled directly from EDGAR's XBRL CompanyFacts API. Click below to view the latest annual report (10-K) in full.

Open latest 10-K on SEC EDGAR →

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.